nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadodiamide—Myocardial ischaemia—Sorafenib—thyroid cancer	0.0169	0.0169	CcSEcCtD
Gadodiamide—Warmth—Epirubicin—thyroid cancer	0.0158	0.0158	CcSEcCtD
Gadodiamide—Cardiac failure—Vandetanib—thyroid cancer	0.015	0.015	CcSEcCtD
Gadodiamide—Hyponatraemia—Vandetanib—thyroid cancer	0.0147	0.0147	CcSEcCtD
Gadodiamide—Warmth—Doxorubicin—thyroid cancer	0.0146	0.0146	CcSEcCtD
Gadodiamide—Blood creatinine increased—Vandetanib—thyroid cancer	0.0137	0.0137	CcSEcCtD
Gadodiamide—Bronchospasm—Vandetanib—thyroid cancer	0.0124	0.0124	CcSEcCtD
Gadodiamide—Renal failure—Vandetanib—thyroid cancer	0.0111	0.0111	CcSEcCtD
Gadodiamide—Renal failure acute—Sorafenib—thyroid cancer	0.0107	0.0107	CcSEcCtD
Gadodiamide—Cardiac failure—Sorafenib—thyroid cancer	0.0101	0.0101	CcSEcCtD
Gadodiamide—Urinary tract disorder—Vandetanib—thyroid cancer	0.00999	0.00999	CcSEcCtD
Gadodiamide—Urethral disorder—Vandetanib—thyroid cancer	0.00992	0.00992	CcSEcCtD
Gadodiamide—Hyponatraemia—Sorafenib—thyroid cancer	0.00991	0.00991	CcSEcCtD
Gadodiamide—Visual impairment—Vandetanib—thyroid cancer	0.00975	0.00975	CcSEcCtD
Gadodiamide—Venous thrombosis—Epirubicin—thyroid cancer	0.00931	0.00931	CcSEcCtD
Gadodiamide—Arrhythmia—Vandetanib—thyroid cancer	0.00904	0.00904	CcSEcCtD
Gadodiamide—Dysgeusia—Vandetanib—thyroid cancer	0.00863	0.00863	CcSEcCtD
Gadodiamide—Venous thrombosis—Doxorubicin—thyroid cancer	0.00861	0.00861	CcSEcCtD
Gadodiamide—Tremor—Vandetanib—thyroid cancer	0.00825	0.00825	CcSEcCtD
Gadodiamide—Loss of consciousness—Vandetanib—thyroid cancer	0.00774	0.00774	CcSEcCtD
Gadodiamide—Convulsion—Vandetanib—thyroid cancer	0.00763	0.00763	CcSEcCtD
Gadodiamide—Arthralgia—Vandetanib—thyroid cancer	0.0075	0.0075	CcSEcCtD
Gadodiamide—Chest pain—Vandetanib—thyroid cancer	0.0075	0.0075	CcSEcCtD
Gadodiamide—Acute coronary syndrome—Sorafenib—thyroid cancer	0.0075	0.0075	CcSEcCtD
Gadodiamide—Renal failure—Sorafenib—thyroid cancer	0.00747	0.00747	CcSEcCtD
Gadodiamide—Anxiety—Vandetanib—thyroid cancer	0.00747	0.00747	CcSEcCtD
Gadodiamide—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00745	0.00745	CcSEcCtD
Gadodiamide—Myocardial infarction—Sorafenib—thyroid cancer	0.00745	0.00745	CcSEcCtD
Gadodiamide—Dry mouth—Vandetanib—thyroid cancer	0.00733	0.00733	CcSEcCtD
Gadodiamide—Oedema—Vandetanib—thyroid cancer	0.00719	0.00719	CcSEcCtD
Gadodiamide—Infection—Vandetanib—thyroid cancer	0.00714	0.00714	CcSEcCtD
Gadodiamide—Lung disorder—Epirubicin—thyroid cancer	0.0071	0.0071	CcSEcCtD
Gadodiamide—Nervous system disorder—Vandetanib—thyroid cancer	0.00705	0.00705	CcSEcCtD
Gadodiamide—Urinary tract disorder—Sorafenib—thyroid cancer	0.00674	0.00674	CcSEcCtD
Gadodiamide—Urethral disorder—Sorafenib—thyroid cancer	0.00669	0.00669	CcSEcCtD
Gadodiamide—Lung disorder—Doxorubicin—thyroid cancer	0.00657	0.00657	CcSEcCtD
Gadodiamide—Rash erythematous—Epirubicin—thyroid cancer	0.00656	0.00656	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00655	0.00655	CcSEcCtD
Gadodiamide—Paraesthesia—Vandetanib—thyroid cancer	0.00646	0.00646	CcSEcCtD
Gadodiamide—Dyspnoea—Vandetanib—thyroid cancer	0.00641	0.00641	CcSEcCtD
Gadodiamide—Feeling hot—Epirubicin—thyroid cancer	0.0064	0.0064	CcSEcCtD
Gadodiamide—Tinnitus—Sorafenib—thyroid cancer	0.00636	0.00636	CcSEcCtD
Gadodiamide—Flushing—Sorafenib—thyroid cancer	0.00634	0.00634	CcSEcCtD
Gadodiamide—Dyspepsia—Vandetanib—thyroid cancer	0.00633	0.00633	CcSEcCtD
Gadodiamide—Ageusia—Epirubicin—thyroid cancer	0.0062	0.0062	CcSEcCtD
Gadodiamide—Fatigue—Vandetanib—thyroid cancer	0.0062	0.0062	CcSEcCtD
Gadodiamide—Rigors—Epirubicin—thyroid cancer	0.00615	0.00615	CcSEcCtD
Gadodiamide—Injection site pain—Epirubicin—thyroid cancer	0.00615	0.00615	CcSEcCtD
Gadodiamide—Pain—Vandetanib—thyroid cancer	0.00615	0.00615	CcSEcCtD
Gadodiamide—Arrhythmia—Sorafenib—thyroid cancer	0.0061	0.0061	CcSEcCtD
Gadodiamide—Rash erythematous—Doxorubicin—thyroid cancer	0.00607	0.00607	CcSEcCtD
Gadodiamide—Feeling hot—Doxorubicin—thyroid cancer	0.00592	0.00592	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00588	0.00588	CcSEcCtD
Gadodiamide—Dysgeusia—Sorafenib—thyroid cancer	0.00582	0.00582	CcSEcCtD
Gadodiamide—Extravasation—Epirubicin—thyroid cancer	0.00576	0.00576	CcSEcCtD
Gadodiamide—Ageusia—Doxorubicin—thyroid cancer	0.00574	0.00574	CcSEcCtD
Gadodiamide—Cardiovascular disorder—Epirubicin—thyroid cancer	0.00572	0.00572	CcSEcCtD
Gadodiamide—Vasodilation procedure—Epirubicin—thyroid cancer	0.00572	0.00572	CcSEcCtD
Gadodiamide—Vasodilation—Epirubicin—thyroid cancer	0.00572	0.00572	CcSEcCtD
Gadodiamide—Injection site pain—Doxorubicin—thyroid cancer	0.00569	0.00569	CcSEcCtD
Gadodiamide—Rigors—Doxorubicin—thyroid cancer	0.00569	0.00569	CcSEcCtD
Gadodiamide—Body temperature increased—Vandetanib—thyroid cancer	0.00568	0.00568	CcSEcCtD
Gadodiamide—Abdominal pain—Vandetanib—thyroid cancer	0.00568	0.00568	CcSEcCtD
Gadodiamide—Syncope—Sorafenib—thyroid cancer	0.00533	0.00533	CcSEcCtD
Gadodiamide—Extravasation—Doxorubicin—thyroid cancer	0.00533	0.00533	CcSEcCtD
Gadodiamide—Vasodilation—Doxorubicin—thyroid cancer	0.00529	0.00529	CcSEcCtD
Gadodiamide—Vasodilation procedure—Doxorubicin—thyroid cancer	0.00529	0.00529	CcSEcCtD
Gadodiamide—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.00529	0.00529	CcSEcCtD
Gadodiamide—Loss of consciousness—Sorafenib—thyroid cancer	0.00522	0.00522	CcSEcCtD
Gadodiamide—Asthenia—Vandetanib—thyroid cancer	0.00516	0.00516	CcSEcCtD
Gadodiamide—Coordination abnormal—Epirubicin—thyroid cancer	0.00512	0.00512	CcSEcCtD
Gadodiamide—Pruritus—Vandetanib—thyroid cancer	0.00509	0.00509	CcSEcCtD
Gadodiamide—Arthralgia—Sorafenib—thyroid cancer	0.00506	0.00506	CcSEcCtD
Gadodiamide—Myalgia—Sorafenib—thyroid cancer	0.00506	0.00506	CcSEcCtD
Gadodiamide—Injection site reaction—Epirubicin—thyroid cancer	0.00499	0.00499	CcSEcCtD
Gadodiamide—Dry mouth—Sorafenib—thyroid cancer	0.00495	0.00495	CcSEcCtD
Gadodiamide—Eructation—Epirubicin—thyroid cancer	0.00494	0.00494	CcSEcCtD
Gadodiamide—Diarrhoea—Vandetanib—thyroid cancer	0.00492	0.00492	CcSEcCtD
Gadodiamide—Melaena—Epirubicin—thyroid cancer	0.00491	0.00491	CcSEcCtD
Gadodiamide—Anaphylactic shock—Sorafenib—thyroid cancer	0.00485	0.00485	CcSEcCtD
Gadodiamide—Infection—Sorafenib—thyroid cancer	0.00482	0.00482	CcSEcCtD
Gadodiamide—Shock—Sorafenib—thyroid cancer	0.00477	0.00477	CcSEcCtD
Gadodiamide—Nervous system disorder—Sorafenib—thyroid cancer	0.00476	0.00476	CcSEcCtD
Gadodiamide—Dizziness—Vandetanib—thyroid cancer	0.00475	0.00475	CcSEcCtD
Gadodiamide—Coordination abnormal—Doxorubicin—thyroid cancer	0.00473	0.00473	CcSEcCtD
Gadodiamide—Injection site reaction—Doxorubicin—thyroid cancer	0.00462	0.00462	CcSEcCtD
Gadodiamide—Coma—Epirubicin—thyroid cancer	0.00459	0.00459	CcSEcCtD
Gadodiamide—Vomiting—Vandetanib—thyroid cancer	0.00457	0.00457	CcSEcCtD
Gadodiamide—Eructation—Doxorubicin—thyroid cancer	0.00457	0.00457	CcSEcCtD
Gadodiamide—Melaena—Doxorubicin—thyroid cancer	0.00454	0.00454	CcSEcCtD
Gadodiamide—Rash—Vandetanib—thyroid cancer	0.00453	0.00453	CcSEcCtD
Gadodiamide—Dermatitis—Vandetanib—thyroid cancer	0.00453	0.00453	CcSEcCtD
Gadodiamide—Headache—Vandetanib—thyroid cancer	0.0045	0.0045	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00442	0.00442	CcSEcCtD
Gadodiamide—Abnormal vision—Epirubicin—thyroid cancer	0.00438	0.00438	CcSEcCtD
Gadodiamide—Dyspnoea—Sorafenib—thyroid cancer	0.00432	0.00432	CcSEcCtD
Gadodiamide—Nausea—Vandetanib—thyroid cancer	0.00427	0.00427	CcSEcCtD
Gadodiamide—Dyspepsia—Sorafenib—thyroid cancer	0.00427	0.00427	CcSEcCtD
Gadodiamide—Coma—Doxorubicin—thyroid cancer	0.00425	0.00425	CcSEcCtD
Gadodiamide—Phlebitis—Epirubicin—thyroid cancer	0.00423	0.00423	CcSEcCtD
Gadodiamide—Fatigue—Sorafenib—thyroid cancer	0.00418	0.00418	CcSEcCtD
Gadodiamide—Pain—Sorafenib—thyroid cancer	0.00415	0.00415	CcSEcCtD
Gadodiamide—Abnormal vision—Doxorubicin—thyroid cancer	0.00405	0.00405	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00397	0.00397	CcSEcCtD
Gadodiamide—Renal failure acute—Epirubicin—thyroid cancer	0.00395	0.00395	CcSEcCtD
Gadodiamide—Phlebitis—Doxorubicin—thyroid cancer	0.00392	0.00392	CcSEcCtD
Gadodiamide—Hot flush—Epirubicin—thyroid cancer	0.0039	0.0039	CcSEcCtD
Gadodiamide—Menopausal symptoms—Epirubicin—thyroid cancer	0.00386	0.00386	CcSEcCtD
Gadodiamide—Urticaria—Sorafenib—thyroid cancer	0.00385	0.00385	CcSEcCtD
Gadodiamide—Abdominal pain—Sorafenib—thyroid cancer	0.00383	0.00383	CcSEcCtD
Gadodiamide—Body temperature increased—Sorafenib—thyroid cancer	0.00383	0.00383	CcSEcCtD
Gadodiamide—Renal impairment—Epirubicin—thyroid cancer	0.00383	0.00383	CcSEcCtD
Gadodiamide—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.00377	0.00377	CcSEcCtD
Gadodiamide—Cardiac failure—Epirubicin—thyroid cancer	0.00374	0.00374	CcSEcCtD
Gadodiamide—Hyponatraemia—Epirubicin—thyroid cancer	0.00366	0.00366	CcSEcCtD
Gadodiamide—Renal failure acute—Doxorubicin—thyroid cancer	0.00365	0.00365	CcSEcCtD
Gadodiamide—Hot flush—Doxorubicin—thyroid cancer	0.00361	0.00361	CcSEcCtD
Gadodiamide—Migraine—Epirubicin—thyroid cancer	0.00359	0.00359	CcSEcCtD
Gadodiamide—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00358	0.00358	CcSEcCtD
Gadodiamide—Hypersensitivity—Sorafenib—thyroid cancer	0.00357	0.00357	CcSEcCtD
Gadodiamide—Renal impairment—Doxorubicin—thyroid cancer	0.00355	0.00355	CcSEcCtD
Gadodiamide—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.00349	0.00349	CcSEcCtD
Gadodiamide—Asthenia—Sorafenib—thyroid cancer	0.00348	0.00348	CcSEcCtD
Gadodiamide—Cardiac failure—Doxorubicin—thyroid cancer	0.00346	0.00346	CcSEcCtD
Gadodiamide—Pruritus—Sorafenib—thyroid cancer	0.00343	0.00343	CcSEcCtD
Gadodiamide—Ataxia—Epirubicin—thyroid cancer	0.00343	0.00343	CcSEcCtD
Gadodiamide—Blood creatinine increased—Epirubicin—thyroid cancer	0.00342	0.00342	CcSEcCtD
Gadodiamide—Hyponatraemia—Doxorubicin—thyroid cancer	0.00339	0.00339	CcSEcCtD
Gadodiamide—Migraine—Doxorubicin—thyroid cancer	0.00332	0.00332	CcSEcCtD
Gadodiamide—Diarrhoea—Sorafenib—thyroid cancer	0.00332	0.00332	CcSEcCtD
Gadodiamide—Dizziness—Sorafenib—thyroid cancer	0.00321	0.00321	CcSEcCtD
Gadodiamide—Ataxia—Doxorubicin—thyroid cancer	0.00317	0.00317	CcSEcCtD
Gadodiamide—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00316	0.00316	CcSEcCtD
Gadodiamide—Vomiting—Sorafenib—thyroid cancer	0.00308	0.00308	CcSEcCtD
Gadodiamide—Rash—Sorafenib—thyroid cancer	0.00306	0.00306	CcSEcCtD
Gadodiamide—Dermatitis—Sorafenib—thyroid cancer	0.00306	0.00306	CcSEcCtD
Gadodiamide—Headache—Sorafenib—thyroid cancer	0.00304	0.00304	CcSEcCtD
Gadodiamide—Nausea—Sorafenib—thyroid cancer	0.00288	0.00288	CcSEcCtD
Gadodiamide—Renal failure—Epirubicin—thyroid cancer	0.00276	0.00276	CcSEcCtD
Gadodiamide—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00275	0.00275	CcSEcCtD
Gadodiamide—Renal failure—Doxorubicin—thyroid cancer	0.00256	0.00256	CcSEcCtD
Gadodiamide—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00255	0.00255	CcSEcCtD
Gadodiamide—Rhinitis—Epirubicin—thyroid cancer	0.00253	0.00253	CcSEcCtD
Gadodiamide—Pharyngitis—Epirubicin—thyroid cancer	0.0025	0.0025	CcSEcCtD
Gadodiamide—Urinary tract disorder—Epirubicin—thyroid cancer	0.00249	0.00249	CcSEcCtD
Gadodiamide—Urethral disorder—Epirubicin—thyroid cancer	0.00247	0.00247	CcSEcCtD
Gadodiamide—Visual impairment—Epirubicin—thyroid cancer	0.00243	0.00243	CcSEcCtD
Gadodiamide—Tinnitus—Epirubicin—thyroid cancer	0.00235	0.00235	CcSEcCtD
Gadodiamide—Flushing—Epirubicin—thyroid cancer	0.00234	0.00234	CcSEcCtD
Gadodiamide—Rhinitis—Doxorubicin—thyroid cancer	0.00234	0.00234	CcSEcCtD
Gadodiamide—Pharyngitis—Doxorubicin—thyroid cancer	0.00232	0.00232	CcSEcCtD
Gadodiamide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Gadodiamide—Urethral disorder—Doxorubicin—thyroid cancer	0.00229	0.00229	CcSEcCtD
Gadodiamide—Chills—Epirubicin—thyroid cancer	0.00226	0.00226	CcSEcCtD
Gadodiamide—Arrhythmia—Epirubicin—thyroid cancer	0.00225	0.00225	CcSEcCtD
Gadodiamide—Visual impairment—Doxorubicin—thyroid cancer	0.00225	0.00225	CcSEcCtD
Gadodiamide—Tinnitus—Doxorubicin—thyroid cancer	0.00218	0.00218	CcSEcCtD
Gadodiamide—Flushing—Doxorubicin—thyroid cancer	0.00217	0.00217	CcSEcCtD
Gadodiamide—Dysgeusia—Epirubicin—thyroid cancer	0.00215	0.00215	CcSEcCtD
Gadodiamide—Chills—Doxorubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Gadodiamide—Arrhythmia—Doxorubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Gadodiamide—Ill-defined disorder—Epirubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Gadodiamide—Dysgeusia—Doxorubicin—thyroid cancer	0.00199	0.00199	CcSEcCtD
Gadodiamide—Malaise—Epirubicin—thyroid cancer	0.00198	0.00198	CcSEcCtD
Gadodiamide—Syncope—Epirubicin—thyroid cancer	0.00197	0.00197	CcSEcCtD
Gadodiamide—Loss of consciousness—Epirubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Gadodiamide—Convulsion—Epirubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Gadodiamide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00189	0.00189	CcSEcCtD
Gadodiamide—Arthralgia—Epirubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Gadodiamide—Chest pain—Epirubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Gadodiamide—Myalgia—Epirubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Gadodiamide—Anxiety—Epirubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Gadodiamide—Discomfort—Epirubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Gadodiamide—Malaise—Doxorubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Gadodiamide—Dry mouth—Epirubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Gadodiamide—Syncope—Doxorubicin—thyroid cancer	0.00182	0.00182	CcSEcCtD
Gadodiamide—Anaphylactic shock—Epirubicin—thyroid cancer	0.00179	0.00179	CcSEcCtD
Gadodiamide—Oedema—Epirubicin—thyroid cancer	0.00179	0.00179	CcSEcCtD
Gadodiamide—Loss of consciousness—Doxorubicin—thyroid cancer	0.00179	0.00179	CcSEcCtD
Gadodiamide—Infection—Epirubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Gadodiamide—Shock—Epirubicin—thyroid cancer	0.00176	0.00176	CcSEcCtD
Gadodiamide—Convulsion—Doxorubicin—thyroid cancer	0.00176	0.00176	CcSEcCtD
Gadodiamide—Nervous system disorder—Epirubicin—thyroid cancer	0.00176	0.00176	CcSEcCtD
Gadodiamide—Tachycardia—Epirubicin—thyroid cancer	0.00175	0.00175	CcSEcCtD
Gadodiamide—Hyperhidrosis—Epirubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Gadodiamide—Arthralgia—Doxorubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Gadodiamide—Chest pain—Doxorubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Gadodiamide—Myalgia—Doxorubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Gadodiamide—Anxiety—Doxorubicin—thyroid cancer	0.00172	0.00172	CcSEcCtD
Gadodiamide—Discomfort—Doxorubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Gadodiamide—Dry mouth—Doxorubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Gadodiamide—Hypotension—Epirubicin—thyroid cancer	0.00167	0.00167	CcSEcCtD
Gadodiamide—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00166	0.00166	CcSEcCtD
Gadodiamide—Oedema—Doxorubicin—thyroid cancer	0.00166	0.00166	CcSEcCtD
Gadodiamide—Infection—Doxorubicin—thyroid cancer	0.00165	0.00165	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00163	0.00163	CcSEcCtD
Gadodiamide—Shock—Doxorubicin—thyroid cancer	0.00163	0.00163	CcSEcCtD
Gadodiamide—Nervous system disorder—Doxorubicin—thyroid cancer	0.00163	0.00163	CcSEcCtD
Gadodiamide—Tachycardia—Doxorubicin—thyroid cancer	0.00162	0.00162	CcSEcCtD
Gadodiamide—Paraesthesia—Epirubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Gadodiamide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Gadodiamide—Dyspnoea—Epirubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Gadodiamide—Somnolence—Epirubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Gadodiamide—Dyspepsia—Epirubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Gadodiamide—Hypotension—Doxorubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Gadodiamide—Fatigue—Epirubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Gadodiamide—Pain—Epirubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Gadodiamide—Paraesthesia—Doxorubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Gadodiamide—Dyspnoea—Doxorubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Gadodiamide—Feeling abnormal—Epirubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Gadodiamide—Somnolence—Doxorubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Gadodiamide—Dyspepsia—Doxorubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Gadodiamide—Fatigue—Doxorubicin—thyroid cancer	0.00143	0.00143	CcSEcCtD
Gadodiamide—Urticaria—Epirubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Gadodiamide—Pain—Doxorubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Gadodiamide—Abdominal pain—Epirubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Gadodiamide—Body temperature increased—Epirubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Gadodiamide—Feeling abnormal—Doxorubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00136	0.00136	CcSEcCtD
Gadodiamide—Hypersensitivity—Epirubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Gadodiamide—Urticaria—Doxorubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Gadodiamide—Abdominal pain—Doxorubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Gadodiamide—Body temperature increased—Doxorubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Gadodiamide—Asthenia—Epirubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Gadodiamide—Pruritus—Epirubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Gadodiamide—Diarrhoea—Epirubicin—thyroid cancer	0.00123	0.00123	CcSEcCtD
Gadodiamide—Hypersensitivity—Doxorubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Gadodiamide—Asthenia—Doxorubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Gadodiamide—Dizziness—Epirubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Gadodiamide—Pruritus—Doxorubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Gadodiamide—Vomiting—Epirubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Gadodiamide—Diarrhoea—Doxorubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Gadodiamide—Rash—Epirubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Gadodiamide—Dermatitis—Epirubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Gadodiamide—Headache—Epirubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Gadodiamide—Dizziness—Doxorubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Gadodiamide—Nausea—Epirubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Gadodiamide—Vomiting—Doxorubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Gadodiamide—Rash—Doxorubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Gadodiamide—Dermatitis—Doxorubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Gadodiamide—Headache—Doxorubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Gadodiamide—Nausea—Doxorubicin—thyroid cancer	0.000985	0.000985	CcSEcCtD
